Molecular structure of Batimastat, CAS Number: 130370-60-4
Batimastat (CAS 130370-60-4)
See product citations (24)
Alternate Names:
BB-94
Application:
Batimastat is a broad spectrum MMP (matrix metalloprotease) inhibitor
CAS Number:
130370-60-4
Purity:
≥98%
Molecular Weight:
477.64
Molecular Formula:
C23H31N3O4S2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Batimastat is a potent, broad spectrum MMP (matrix metalloprotease) inhibitor, with IC50 values of 3, 4, 4, 6 and 20 nM for MMP-1, MMP-2, MMP-9, MMP-7 and MMP-3 respectively, that has demonstrated antiproliferative, anti-invasive and antimetastatic activity. Batimastat also demonstrated the ability to reduce tumor size and inhibit metastasis in mice implanted with human colon carcinoma cells. Batimastat, also known as BB-94, is a synthetic compound that serves as a non-peptide inhibitor of matrix metalloproteinases (MMPs). It is extensively utilized in laboratory experiments to explore the involvement of MMPs in various biological processes. Batimastat is a small molecule designed to specifically bind to the active site of MMPs, thereby hindering their ability to cleave substrates. Notably, it exhibits a strong affinity for MMP-2 and MMP-9 and surpasses other MMP inhibitors in terms of potency. The interaction between batimastat and the active site of MMPs induces a structural alteration in the enzyme, effectively impeding its substrate cleavage function.
Batimastat (CAS 130370-60-4) References
- Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model. | Lein, M., et al. 2000. Prostate. 43: 77-82. PMID: 10754522
- Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. | Krüger, A., et al. 2001. Cancer Res. 61: 1272-5. PMID: 11245418
- Inhibition of bleomycin-induced pulmonary fibrosis in mice by the matrix metalloproteinase inhibitor batimastat. | Corbel, M., et al. 2001. J Pathol. 193: 538-45. PMID: 11276015
- Batimastat reduces Mycobacterium tuberculosis-induced apoptosis in macrophages. | Santucci, MB., et al. 2003. Int Immunopharmacol. 3: 1657-65. PMID: 14555290
- Influence of the matrix metalloproteinase inhibitor batimastat (BB-94) on periodontal bone destruction in Sprague-Dawley rats. | Björnsson, MJ., et al. 2004. J Periodontal Res. 39: 269-74. PMID: 15206921
- Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice. | Kumar, A., et al. 2010. Am J Pathol. 177: 248-60. PMID: 20472898
- Batimastat nanoparticles associated with transcatheter arterial chemoembolization decrease hepatocellular carcinoma recurrence. | Xiao, L. and Wang, M. 2014. Cell Biochem Biophys. 70: 269-72. PMID: 24639109
- Fluorescent Analogue of Batimastat Enables Imaging of α-Secretase in Living Cells. | Leriche, G., et al. 2016. ACS Chem Neurosci. 7: 40-5. PMID: 26559179
- Repurposing Cancer Drugs Batimastat and Marimastat to Inhibit the Activity of a Group I Metalloprotease from the Venom of the Western Diamondback Rattlesnake, Crotalus atrox. | Layfield, HJ., et al. 2020. Toxins (Basel). 12: PMID: 32397419
- The Matrix Metalloproteinase Inhibitor Batimastat Reduces Epidural Fibrosis After Laminectomy in Rats. | Yurtal, Z., et al. 2023. Turk Neurosurg. 33: 162-170. PMID: 36482856
- Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. | Sledge, GW., et al. 1995. J Natl Cancer Inst. 87: 1546-50. PMID: 7563189
- Molecular insights into cancer invasion: strategies for prevention and intervention. | Kohn, EC. and Liotta, LA. 1995. Cancer Res. 55: 1856-62. PMID: 7728753
- Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. | Wang, X., et al. 1994. Cancer Res. 54: 4726-8. PMID: 8062271
- A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. | Davies, B., et al. 1993. Cancer Res. 53: 2087-91. PMID: 8347186
- Batimastat (BB-94) inhibits matrix metalloproteinases of equine laminitis. | Pollitt, CC., et al. 1998. Equine Vet J Suppl. 119-24. PMID: 9932102
Inhibitor of:
2900024O10Rik, ADAM, ADAM11, ADAM2, ADAM20, ADAM21, ADAM23, ADAM24, ADAM25, ADAM26, ADAM26B, ADAM29, ADAM30, ADAM32, ADAM34, ADAM38, ADAM39, ADAM6B, ADAM7, ADAM9, ADAMTS-13, ADAMTS-17, ADAMTS-19, ADAMTS-20, ADAMTS-8, ADAMTS-9, ADAMTS-L5, AMZ1, C8γ, CEACAM16, CLAP, COL19A1, COL1A1, COL22A1, COL6A2, COL6A4, COL9A1, Collagen α1, CPA4, CPM, CPXM2, Ddc8, Dispase I, EG384813, EGFL11, EGFL3, EGFL8, EMID1, FIBCD1, fibrillin-3, Fibulin-7, Filamin β, HAPLN3, HB-EGF, hemicentin-2, Hmcn2, Intectin, Integrin αE, ITFG3, JAM (junction adhesion molecule), Laminin β-2, Laminin β-4, Laminin γ-3, LMLN, LYPD1, Mast Cell Protease 4, Mast Cell Protease 5, Mast Cell Protease 9, MBLAC2, MCC, Meprin A, Meprin A alpha, Meprin Aβ, METH-1, Microfibril associated protein (MFAP), MMP-1, MMP-10, MMP-1a, MMP-1b, MMP-2, MMP-20, MMP-3, MMP-7, MMP-8, MMP-9, MT-MMP-1, MUP21, MUP7, MUP8, MUP9, murinoglobulin 1, MXRA5, MXRA7, NAALADL2, NET-7, Ninjurin-2, OTTMUSG00000008561, PCPE-1, PEPD, PF4V1, PHEX, pilD, PRG-3, PTPy, Rhomboid, SPPL3, SSc5D, TACE, TATI, Tenascin-R, TIMP-1, TIMP-2, TIMP-3, TIMP-4, TIN-Ag, TLL1, TLL2, TNFa-IP 8, VWA8, WARP, WECHE, and ZPLD1.Activator of:
ADAM18, ADAM21, ADAM24, ADAM25, ADAM6A, ADAM8, CD154, CMG1, ephrin-A4, LMLN, Meprin A, MICB, MMP-19, MMP-1b, MT-MMP-1, MT-MMP-4, MT-MMP-6, NPEPL1, and SERPINE3.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Batimastat, 1 mg | sc-203833 | 1 mg | $179.00 | |||
Batimastat, 10 mg | sc-203833A | 10 mg | $377.00 |